ADMA vs CUBE · P/E 22, rev $426.5M vs P/E 25, rev $1.07B
ADMA Biologics Inc (ADMA) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
ADMA Biologics Inc (ADMA) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported ADMA revenue for 2024-12-31 was $426.5M. Net income was $197.7M. Revenue was up 65.2% from 2023-12-31 to 2024-12-31. ADMA currently screens at market cap $4.39B and trailing P/E 21.9.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
ADMA currently screens at market cap $4.39B and trailing P/E 21.9. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the ADMA and CUBE stock pages for the full models.
Not investment advice.